The United States Food and Drug Administration has just approved the first drug in pill form that restores hair growth in people suffering from alopecia.

The US Food and Drug Administration announced that it has approved the drug “Baristinib” under the trade name Olumiant, after achieving good results in the third and final clinical trial.

Baristinib was originally developed as a treatment for rheumatoid arthritis, but scientists have found that it has a positive effect on patients with alopecia whose hair falls out due to immune system attacks on hair follicles.
Scientists have started to study the ability of baricinib in the area of ​​alopecia, based on the fact that it can disrupt signaling pathways that damage hair follicles.

Results from the third phase of the study, in which about 1,200 people suffered from alopecia, showed that about a third of them could grow their hair by taking 4 milligrams of Parisinib a day, according to the New Atlas. It specializes in scientific and technical innovations.

Doses of 2 milligrams also improved scalp hair coverage in nearly a fifth of patients.

It is worth mentioning that more than 300,000 people in the United States suffer from alopecia each year.